The FDA is finalizing guidelines that will eliminate the requirement that drugmakers conduct follow-up studies for new drugs to treat resistant HIV/AIDS. The move is meant to reduce the research time needed for approval of new treatments and provide more treatments for longtime patients.

Full Story:

Related Summaries